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Abstract
The hepatitis E virus (HEV) is one of the main causes of acute hepatitis and the de 
facto global burden is underestimated. HEV- related clinical complications are often 
undetected and are not considered in the differential diagnosis. Convincing findings 
from studies suggest that HEV is clinically relevant not only in developing coun-
tries but also in industrialized countries. Eight HEV genotypes (HEV- 1 to HEV- 8) 
with different human and animal hosts and other HEV- related viruses are in circu-
lation. Transmission routes vary by genotype and location, with large waterborne 
outbreaks in developing countries and zoonotic food- borne infections in developed 
countries. An acute infection can be aggravated in pregnant women, organ trans-
plant recipients, patients with pre- existing liver disease and immunosuppressed pa-
tients. HEV during pregnancy affects the fetus and newborn with an increased risk 
of vertical transmission, preterm and stillbirth, neonatal jaundice and miscarriage. 
Hepatitis E is associated with extrahepatic manifestations that include neurological 
disorders such as neuralgic amyotrophy, Guillain- Barré syndrome and encephalitis, 
renal injury and haematological disorders. The risk of transfusion- transmitted HEV 
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1  | INTRODUC TION
Hepatitis E virus (HEV) is one of the leading causes of acute hepatitis 
in developing and developed countries, infecting about 20 million 
people in developing countries, resulting in 3.3 million symptomatic 
cases and 44 000 deaths per year.1 HEV not only infects hepato-
cytes, but also extrahepatic tissues.2 Studies on HEV seroprevalence 
have shown that it causes a significant burden, and one- third of the 
world population is infected at least once in their lives.1 HEV is a 
single- stranded RNA virus and belongs to the genus Orthohepevirus 
with the species Orthohepevirus A, B, C and D within the Hepeviridae 
family. It is known that the Orthohepeviruses A, C and D infect mam-
mals.3 Orthohepevirus A comprises eight genotypes, HEV- 1 to HEV- 
8,4 and all eight belong to a single serotype.5 The HEV- 1 to HEV- 4 
and HEV- 7 genotypes are known to infect humans.
HEV- 1 and HEV- 2 are transmitted via the faecal- oral route. 
On the other hand, HEV- 3 and HEV- 4 infect humans and animals 
mainly in developed countries and are transmitted zoonotically 
through the consumption of undercooked pork, contact with wild 
animals or via blood transfusion. A recent review indicates varying 
seroprevalences (0.03%- 52%) in western countries, with the highest 
prevalence reported from the Netherlands, Germany and France.6 
Most acute HEV infections are self- limiting and resolve within a few 
weeks without treatment. However, deaths are reported because of 
fulminant hepatitis in 0.5%- 4% of patients in different geographical 
regions.7 Currently, there are no approved drugs or vaccines against 
HEV infections, but patients are treated with broad- spectrum anti-
viral drugs, PegIFN2alpha and ribavirin (RBV) as mono- or combina-
tion therapy. The only HEV vaccine Hecolin®, is solely approved and 
available in China.
This review of hepatitis E aims to provide updates on the current 
literature relevant to One Health and clinical medicine.
2  | ZOONOSES AND ONE HE ALTH
The spillover of pathogens from animal hosts to people termed 
‘Zoonotic transmission is increasingly recognized and is a major 
contributor to many emerging infectious diseases.8 The One Health 
notion acknowledges the interdependence of human, animal and 
environmental health.9,10 It is a collaborative, multi- disciplinary ap-
proach that aims in the promotion, improvement, and defense for 
the health and well- being of all species.11 Since HEV infections can 
be transmitted zoonotically, they should be considered under the 
One Health concept to prevent the spread of HEV from animal hosts 
to humans.
HEV infections are identified in a wide range of animal spe-
cies12,13 (Table 1). This includes domestic animals, companion, zoo 
and wild animals. Some animal species harbour specific HEV genera 
or genotypes, adapted to them and are predominantly found within 
these species as a virus reservoir.12 In other animal species, only a 
few isolated infections have been reported with low prevalence.13
There is increasing incidence of hepatitis E throughout 
Europe,14 and much is still unknown about its distribution, sources 
and transmission routes in humans and animals.15,16 A collabora-
tive network "HEVnet" (https://www.rivm.nl/en/hevnet) uses the 
"One Health" approach to understand the HEV sources and trans-
mission routes by molecular epidemiology, thus supporting the 
prevention and control.15 Similarly, several other initiatives fol-
low the "One Health" concept and create One Health surveillance 
is increasingly recognized in Western countries where the risk may be because of 
a zoonosis. RNA testing of blood components is essential to determine the risk of 
transfusion- transmitted HEV. There are currently no approved drugs or vaccines for 
HEV infections. This review focuses on updating the latest developments in zoon-
oses, screening and diagnostics, drugs in use and under development, and vaccines.
K E Y W O R D S
diagnostics, drugs, hepatitis E, infection, vaccines, zoonoses
Key points
• Hepatitis E virus (HEV) is also transmitted zoonotically 
and should be considered under a One Health concept 
to prevent the spread from animal hosts to humans.
• An acute HEV infection can be aggravated in pregnant 
women, organ transplant recipients, patients with pre- 
existing liver disease, HIV- infected and cancer patients 
receiving chemotherapy.
• HEV infections are associated with extrahepatic mani-
festations including neurological disorders.
• HEV RNA in blood and stool indicates an acute or chronic 
infection, and the risk of transfusion- transmitted HEV is 
increasingly recognized.
• There are no approved drugs and the only vaccine 
Hecolin® is solely licensed in China.
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databases to understand the epidemiology of hepatitis E distribu-
tion in humans, animals and environmental samples in European 
countries.17,18
Within Orthohepevirus A (Table 2), the human- pathogenic 
HEV- 3 and - 4 have been shown to be widely distributed in domes-
tic pigs and wild boars, indicating a potential virus reservoir.12 In 
addition, these genotypes have been detected in a wide range of 
other mammalians including cattle, horse, goat, dog, cat and sheep; 
however, in most cases they occur at low prevalences.13 In addi-
tion, HEV- 3 has been detected in several deer species and human 
hepatitis E cases have been described after consumption of deer 
meat.19 However, recent analyses indicate that deer is only infected 
by close contact to infected wild boars, thus arguing against a true 
virus reservoir function for these animals.20 Furthermore, HEV- 5 
and HEV- 6 have only been sporadically detected in wild boars in 
Japan so far. However, a recent study showed that HEV- 5 can in-
fect cynomolgus monkeys, thus, indicating a zoonotic potential.21 
HEV- 7 is specifically observed in camel populations and is prevalent 
in dromedary camels in North and East Africa, United Arab Emirates 
and Pakistan.22 A case of chronic human infection with HEV- 7 has 
been described in 2016 in an immunosuppressed patient who reg-
ularly consumed camel meat and milk.23 HEV- 8 has only recently 
been identified in Bactrian camels from China.24 Although it has not 
been detected in humans so far, it was recently demonstrated to 
be capable of infecting cynomolgus macaques indicating a HEV- 8 
related emerging zoonosis.25
Rabbits are infected with viruses from a specific clade of geno-
type 3 (rabbit HEV or genotype 3ra), pointing out for a host specific-
ity for this virus.26 This virus type is broadly distributed in domestic 
and wild rabbits in many countries of the world.27 The first human 
infections with rabbit HEV were described in France in 2017, where 
one immunocompetent patient with underlying cirrhosis and four 
immunocompromised patients were affected.28 Recently, additional 
rabbit HEV infections have been reported in three solid organ trans-
plant recipients from Switzerland.29
Orthohepevirus C contains viruses infecting rats, ferrets and 
minks. The rat HEV was first identified in 2010 in wild Norway rats 
from Germany.30 Meanwhile, it has been shown to be widely distrib-
uted in different species worldwide indicating its broad circulation 
in rats.31,32 As the rat HEV genome shares only <56% nucleotide se-
quence identity with HEV- 1 to - 4, the zoonotic potential of this virus 
was initially assessed to be low.33 However, a first indication, that the 
virus can also infect mammals, came from its detection in a brown 
bear in 2017.34 Thereafter, a first human case of persistent hepatitis 
caused by rat HEV was published in 2018 affecting an immunosup-
pressed liver transplant patient in Hong Kong.19 One year later, rat 
HEV was described as the etiological agent of severe acute hepatitis 
in an immunocompetent patient from Canada.35,36 Meanwhile ad-
ditional seven patients with rat HEV infection have been identified 
in Hong Kong,35 indicating an emergence of this virus.37 Although 
similar rat HEV strains have been identified in rats from Hong Kong, 
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Representatives of the other virus species within the family 
Hepeviridae have not been found in humans so far and are there-
fore not considered as zoonotic agents. Orthohepevirus B is known 
to occur in birds, especially in chicken,38 whereas Orthohepevirus D 
in bats.38 The viruses of the genus Piscihepevirus have so far only 
been detected in cutthroat trouts and are suspected to solely infect 
fish species.38
Well- investigated transmission pathways of zoonotic HEV geno-
types from animals to humans include occupational exposure,39 con-
sumption of undercooked meat and meat products prepared from 
infected animals.12 However, contamination of other food types, 
eg shellfish or berries, by contaminated irrigation water or fertilizer 
originating from pigs, have been supposed as another possible food-
borne transmission route. In addition, transmission through contact 
with environmental water sources contaminated by animals, has also 
been suggested.
The foodborne transmission of HEV is of particular interest, 
because it is assumed to be one of the most important routes and 
measures of food hygiene may be applied to prevent virus trans-
mission. Therefore, studies have investigated the presence of HEV 
RNA in meat and meat products, indicating prevalences of 0%- 21% 
in domestic pig livers and 2%- 38% in wild boar livers in different 
countries of the world.12,40,41 In processed meat products contain-
ing porcine liver such as liver sausages, the detection rates are even 
higher (between 16% and 47%), which may be explained by mixing 
the livers from several animals into one product. However, detection 
of HEV RNA does not necessarily mean the presence of infectious 
virus as HEV may be inactivated during the food production pro-
cess. Because of the lack of a robust and easy- to- perform cell culture 
system for HEV infectivity measurement, only a few studies could 
demonstrate infectivity directly in food.42 Inactivation of HEV has 
therefore only been analysed using cell culture- adapted strains or 
experimental inoculations into pigs.43 A cell culture study indicated, 
that heating for 70°C for 2 min is sufficient for a >3.9 log decrease 
of infectivity.44 In contrast, heating at 71°C for 20 min was necessary 
in order to completely inactivate HEV present in a liver paté as as-
sessed by experimental inoculation into pigs.45 Other factors usually 
applied for conservation of food are lowering pH and increasing salt 
concentrations. However, recent investigations using a cell culture 
isolate indicate a very high stability of HEV against pH 2- 9 as well as 
against the highest salt concentrations usually applied during meat 
production.46,47 Consumption of under- cooked raw meat products, 
should therefore be avoided by individuals who are at high risk for 
development of severe hepatitis E.
3  | HEPATITIS E IN DISTINC T 
POPUL ATIONS
3.1 | Pregnant women
Hepatitis E virus- 1 during pregnancy is associated with increased 
rates of premature delivery, miscarriage and stillbirths, in developing 
and low- middle income countries.48 The clinical complications often 
include acute liver failure, bleeding and eclampsia gravidarum. It is 
believed that hormonal (progesterone and oestrogen) and exist-
ing immune conditions, high viral loads, nutritional status and host 
factors may promote fatal HEV- 1 courses during pregnancy.49,50 In 
endemic regions, pregnant women infected with HEV- 1 in the third 
trimester are at high risk with relative mortality and morbidity of 
~15%- 60%.51 HEV- 1 related deaths were high among pregnant 
women in Bangladesh.52 The 1986- 1988 outbreak in China re-
ported 119 000 cases causing 707 deaths, including 414 pregnant 
women.53 Also, HEV seroprevalence among pregnant women in 
Africa is between 29% and 84% among women in Egypt, with a low 
seroprevalence of 6.6% in Gabon.54 Despite high seroprevalence in 
Egypt, no related deaths have been documented. Several host and 
viral factors could be responsible for the variations in the outcomes. 
Host genetic factors such as mutations in progesterone receptors 
(PROGINs: 320bp Alu insertion in intron G, V660L and H770H) 
were shown to modulate immune responses.55 The PROGIN poly-
morphisms are associated with the clinical course in pregnancy.56 
Acute and chronic HEV- 3 infections in pregnancy were also reported 
in pregnant women, but the infections resolved eventually without 
any complications.57,58
3.2 | Solid organ transplant recipients and other 
immunocompromised individuals
A subgroup of patients undergoing solid organ transplantation (SOT) 
(eg heart, kidney, liver and renal pancreas) appear to develop chronic 
HEV infection. Natural course of infection is not fully understood, 
but rapid progression to cirrhosis has been reported. These patients 
are high- risk groups for HEV infection because of their immunosup-
pressive status.59 Patients on immunosuppressive drugs, such as 
mTOR inhibitors, have a higher risk of chronic infection.60,61 In ad-
dition, lymphocyte counts and viral diversity have been associated 
with chronic progression of HEV infection in 40%- 70% of immuno-
suppressed patients.62,63 The overall prevalence of HEV infection in 
SOT recipients in Western Europe varies between 0.7% and 1.5%, 
but is higher (3.2%) in lung transplant recipients.64- 66 Persistent HEV 
infections are reported in patients with inherent immunodeficien-
cies67 or individuals receiving immune- modulating agents for auto-
immunity and malignancies.60,68,69
3.3 | New implications
Hepatitis E virus primarily infects liver tissue, but also replicates in 
non- hepatic tissue such as brain, placenta, kidney, small intestine and 
spleen, possibly associated with extrahepatic manifestations.2 In ad-
dition, cross- reactive immune responses may lead to tissue damage 
in other organs.70 The most commonly observed extrahepatic mani-
festations include neurological disorders such as neuralgic amyotro-
phy (NA), Guillain- Barré syndrome (GBS), encephalitis, renal injuries 
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and haematological disorders.71,72 Studies show that about 5%- 10% 
of GBS patients were diagnosed with HEV infections.73- 76 HEV RNA 
was detected in cerebrospinal fluid samples from patients with GBS 
and NA.77- 80 The nucleic acid sequences from GBS patients revealed 
HEV quasispecies compartmentalization,80 and this explains the 
emergence of novel neurotropic HEV variants. Neurological symp-
toms are seen among patients infected with HEV- 1 in Asia,74 and in 
acute and chronic patients infected with HEV- 3.73 In vitro studies 
show that HEV- 3 proliferates efficiently in neuroblastoma cells.81 
Moreover, In addition to central nervous system infections, HEV can 
cause impairment of kidney function.82
4  | SCREENING AND DIAGNOSIS
The clinical symptoms of acute hepatitis E are non- specific and re-
semble the symptoms of hepatitis A.83 The incubation period of HEV 
lasts 2- 9 weeks (15- 64 days) in case of an acute infection (Figure 1). 
RNA can usually be detected in blood 2- 6 weeks after infection and 
in stool for about 2 weeks longer. HEV- specific immunoglobulin M 
(IgM) antibodies appear in the circulation 3- 4 weeks post- infection 
and persist between four and six months,84,85 whereas immuno-
globulin G (IgG) antibodies remain detectable for several years after 
recovery.84,86,87
4.1 | Serology
Enzyme- linked- immune- assays (ELISAs) or immunoblot assays are 
widely used in serology. Serological markers, either antigen (HEV 
antigen) or antibodies (IgM and IgG) are used in the diagnosis of 
acute and chronic infections. Many of these tests use antigens or 
peptides of the immunodominant epitopes (ORF2 and/or ORF3), 
and recombinant antigens show higher sensitivity than shorter pep-
tides.,88 HEV antigens are detected between one to three weeks 
after infection and may persist up to seven weeks in the serum.89 
HEV antigen is expressed higher in immune- compromised patients 
than immune- competent individuals.90 ORF2 Ag assays are used 
for direct viral detection. This assay detects capsid protein in serum 
samples with a specificity of 100%.90 Because of its limited sensitiv-
ity the ORF2 Ag ELISA is not commonly used in routine diagnos-
tics.91 However, there are data showing that detection of ORF2 Ag 
may indicate an acute infection more reliably than a positive anti- 
HEV IgM result.92 As an alternative, anti- HEV IgM based point- of- 
care immune- chromatographic assays are in use in resource- limited 
countries.
4.2 | Nucleic acid testing
The presence of HEV RNA in blood and stool is an indication of 
acute or chronic HEV infection. HEV nucleic acid testing (NAT) as-
says are sensitive, reliable and can detect RNA concentrations as 
low as 7 IU/mL and can be used together with serological assays 
to confirm the diagnosis of HEV infection.93 There are several com-
mercial and in- house NAT assays for the detection of HEV in blood 
and stool. Detection of HEV RNA in urine for diagnostic purposes 
is currently not recommended since there is only limited data avail-
able from chronically infected patients with diagnostic sensitivities 
of <50%.94 Although reliable, there is little variation in test results, 
largely because of the primer targets, between genotypes and sub- 
genotypes.95 Furthermore, the sensitivity of NAT differs among 
commercial kits and laboratories, because of RNA input volume.96 
To address these discrepancies, WHO has developed international 
standards and reference panels for HEV- 1 to HEV- 4.96,97 Assays 
used for screening of HEV in blood, stool, solid organs and stem 
F I G U R E  1   Course of hepatitis E virus 
(HEV) infection: HEV- RNA concentrations 
in serum and faeces indicated in gradient 
(HEV- RNA), biochemical (ALT, alanine 
aminotransferase) and serological markers 
(IgM and IgG: immunoglobulins) during 
and after HEV infection. Dashed line 
represents usual ALT pattern of patients 
presenting with a moderate ALT increase
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cell transplants include conventional reverse transcriptase- PCR 
(RT- PCR), nested PCR, real- time RT- PCR, digital droplet real- time 
RT- PCR, transcription- mediated amplification (TMA), loop- mediated 
isothermal amplification assay (RT- LAMP).82,98,99 HEV RT- PCR, 
nested PCR and LAMP assays can be used as qualitative, whereas, 
real- time RT- PCR, digital droplet real- time RT- PCR and TMA 
methods can quantify HEV copies with a limit of detection as low 
as 7- 20 IU/mL.84,93 TMA methodology is used in high throughput 
screening in blood samples.100 One- step RT- LAMP single- tube test 
is able to detect 11 copies/reaction and has been suggested for use 
as a point- of- care diagnostics.98
4.3 | Blood donors
RNA- testing of blood components are essential in order to deter-
mine the risk of transfusion- transmitted HEV. The screening of 
blood components is performed either selectively (in individuals or 
in pools) or universally, in accordance with national guidelines.101 
A first systematic prospective study conducted in the United 
Kingdom in 2012- 2013 revealed that immune suppressed patients 
were at risk of acquiring HEV through blood transfusions.102 HEV 
RNA testing was introduced in UK since 2016 to prevent trans-
fusion transmitted HEV infection, and later implemented as uni-
versal screening. Since November 2012, over 3.2 million blood 
donor samples have been tested for HEV RNA in the EU and the 
study reports that one in 3,109 donations is HEV RNA positive.101 
Transfusion associated HEV infections were well- documented in 
UK, Japan and among other European nations.103 As there is a high 
risk of transfusion- transmitted HEV infections, seven countries 
in the European Union including Ireland, Netherlands, France, 
Germany, Spain, Austria and Luxembourg implemented universal 
and/or selective HEV RNA screening.101 It is important to note 
that blood donor screening has to be performed with HEV- RNA 
testing as HEV antibodies are frequently negative in viraemic 
asymptomatic blood donors.104
5  | TRE ATMENT OPTIONS
Most of acute HEV infections are self- limiting, as the disease ap-
pears mild in immunocompetent patients and therefore supportive 
management can be recommended. However, acute infection can 
be aggravated in immunocompromised patients, in particular organ 
transplant recipients, HIV- infected patients and cancer patients 
receiving chemotherapy. Acute- on- chronic liver failure because 
of HEV infection is an increasing concern in western countries. 
Currently there are no approved drugs for treatment, but patients 
are treated with broad- spectrum antiviral drugs, PegIFN2alpha 
and RBV. However, both drugs are contraindicated for use in preg-
nant women. Treatment indications and algorithms have been sug-
gested in guidelines developed by the European Association for the 
Study of the Liver in 2018.105 Several RBV- associated mutations 
have been described,106 with G1634R being the most prominent 
and best characterized so far.107- 109 However, a recent multicenter 
study showed that these mutations had no effect on the RBV treat-
ment outcome.110 Furthermore, the lack of a robust HEV cell culture 
models has hampered the development of new antiviral HEV drug 
candidates. Only little is known about potential virus- host interac-
tion partners.111 A newly developed system raises hope, that this 
fact will be banned from future articles and new leverage points for 
intervention strategies can be identified.112 Two strategies are cur-
rently used to identify lead compounds: drug repurposing and de 
novo screening from natural products or raw extracts or chemical 
screens. The drug candidates can target viral proteins or host pro-
teins; direct- acting antiviral drugs are the drugs that act against the 
viral proteins. In contrast, indirect- acting antiviral drugs act on the 
host target proteins.113
Sofosbuvir (SOF) is a nucleotide prodrug, used to treat chronic 
HCV infections in combination with RBV, PegIFN2alpha and 
others.114 The drug binds to NS5B- RNA- dependent RNA poly-
merase of HCV and inhibits viral replication.115 Several in vitro 
studies in Huh7 and HepG2 cells against HEV- 3 genotype and in 
induced pluripotent stem cell- like cells against HEV- 1 to HEV- 4 
showed promising antiviral activity.116 However, no antiviral ac-
tivity was observed in HEK293, U- 87MG and Huh7 cell lines.117 
Furthermore, clinical case studies with SOF in combination with 
RBV showed mixed results; some patients cleared HEV and some 
not.118- 120 Recently, a multicenter HepNet pilot study was con-
ducted in Europe to treat chronic hepatitis E with SOF only in 
those patients who did not respond to RBV treatment (Clinical 
trial. gov ID: NCT03282474).121 This study documented that SOF 
was able to reduce HEV viral load but was unable to eliminate HEV 
in immunocompromised patients.
Netzler et al investigated few approved or potential antiviral 
drugs in various preclinical phases of development against other vi-
ruses such as HCV, influenza and dengue virus.122 Two candidates, 
NITD008 and GPC- N114, showed promising strong anti- HEV activ-
ity, and the combination of these drugs showed strong synergistic 
activity. However, the candidate NITD008 in preclinical studies in 
rats and dogs reported cytotoxic activity.122
Qu et al screened a library of over 1000 FDA approved drugs 
and found deptropine, a histamine H1 receptor antagonist, to be 
a potent inhibitor of HEV replication.123 As HEV causes hepatic 
and extrahepatic manifestations, the drugs were screened in mul-
tiple cell lines. In the Hep3B cell model, treatment with deptropin 
potentially inhibits HEV without affecting cell viability, excluding 
the antiviral effect of deptropin through non- specific cytotoxicity. 
Nisiyama et al performed an extensive screening of 27 antiviral 
compounds using Gaussia luciferase reporter assays. Several classes 
of repurposed drugs have been tested, including RBV and SOF.124 
This study found that combinations of interferons (IFNs), RBV, SOF 
and 2'- C- methylguanosine (2CMG) show promising synergistic 
effects.124
Silvestrol, a natural compound, is known to inhibit the host- 
directed eukaryotic RNA helicase, required for the unwinding of RNA 
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in the 5′- UTRs of mRNAs.125 Originally, this drug was first shown to 
be a potent anti- cancer agent in human breast, prostate and hepa-
tocellular carcinoma graft models and is well- tolerated.126 This com-
pound has been screened for antiviral activity for other viruses.127 It 
was recently evaluated for potential antiviral activity against HEV- 3 
infected A549 cells, and was shown to inhibit HEV replication with-
out cytotoxicity.128 In another study, the antiviral activity of silves-
trol was tested on HepG2/C3A, Huh7.5 and hepatocyte- like cells 
from human embryonic and induced pluripotent cell lines infected 
with HEV- 1 to HEV- 4 genotypes.129 It is shown that silvestrol de-
creases the HEV replication in a dose- dependent manner. In vivo 
inhibitory effect in human chimeric liver mice infected with HEV is 
also reported.129 Both in vivo and in vitro studies show promising 
antiviral activity and may be a potential candidate.
Recently, FDA- approved T- cell specific immunotherapies for the 
treatment of cancers.130 It is known that pathogen- specific effector 
T- cells play an essential role in controlling acute viral infections, mak-
ing T- cell therapy an attractive alternative to currently used thera-
pies.131 Several T- cell- based therapies are now in development for 
the treatment of viral and bacterial infections.132 Soon et al showed 
that HLA- A2- restricted HEV- specific T- cell epitopes targeting HEV 
RNA helicase and RNA- dependent RNA polymerase were identified 
in patients with acute- resolving HEV infection. In vitro studies have 
shown that engineered HEV- specific CD8+ T- cells from chronic 
hepatitis E patients could recognize the HEV- specific epitopes and 
kill the target cells.133
Interferons are cytokines secreted by host cells as cellular im-
mune response to viral infections. IFNs trigger interferon- stimulated 
genes when binding to IFNR, the key antiviral factor in fighting in-
fections.68 Type I IFNs have been used for the standard treatment of 
HCV and HBV infections.134 Todt et al evaluated the antiviral activ-
ity of IFN- α (type I), IFN- γ (type II) and IFN- λ3 (type III) against HEV 
alone or in combination with RBV in cell culture models and found 
that the interferons IFN- γ and IFN- λ3 have a moderate activity and 
the IFNα2a subtype has the strongest antiviral activity.135 However, 
there were no synergistic effects observed when interferon com-
bined with RBV. Another study showed that the interferons IFN- α2b, 
IFN- λ1, IFN- λ2 and IFN- λ3 in combination with SOF or 2CMG were 
synergistically able to inhibit growth and clear HEV in cultures.124
6  | VACCINES
Currently, several HEV vaccine candidates are under development. 
However, Hecolin® is the only licensed vaccine available in China 
since 2012.136 The vaccine is a recombinant truncated ORF2 protein 
HEV239 (aa368- 606) containing 23nM VLPs. This vaccine has un-
dergone several clinical trials, with the administration of three doses 
(0, 28 and 180 days). The phase III clinical trial conducted in 112 604 
healthy adults (16- 65 years) showed that this vaccine was safe and 
efficacious.136 This vaccine had >99% efficacy against HEV among 
adults who were followed up for four and half years.137 However, the 
primary endpoint of the trial was prevention of symptomatic acute 
hepatitis but not prevention of infection. Thus, the vaccine does yield 
sterilizing immunity. Another trial evaluated the immunogenicity and 
safety for an accelerated vaccination regimen (0, 7 and 21 days) and 
was safe (Clinical trial.gov; ID: NCT03168412).138 This dosage regi-
men can be recommended for travellers visiting an HEV- endemic 
regions or used during an HEV outbreak. In addition, another clini-
cal study (Clinical trial.gov; ID: NCT02417597) conducted in healthy 
adults >65 years of age concluded that Hecolin®, with protective 
efficacy of 96%, is safe and well- tolerated.139 These clinical trials 
were conducted in China, where HEV- 4 is the most predominant 
circulating genotype. Thus, the vaccine provided cross- genotype ef-
ficacy as Hecolin® is based on a HEV- 1 sequence. In parallel, a small 
phase Ia/Ib clinical trial in USA is underway, to address the safety 
and tolerability in western population (Clinical trial.gov identifier: 
NCT03827395). Although a handful of clinical studies with a protec-
tive efficacy of more than 90% have been documented, further stud-
ies are warranted in high- risk populations such as pregnant women, 
solid transplant recipients and immune- compromised populations. 
An efficacy study is currently underway in Bangladesh among non- 
pregnant females (age 18- 45) with Hecolin® vaccine (Clinical trial.
gov identifier: NCT02759991).
Along with Hecolin®, several HEV candidate vaccines are cur-
rently being developed and target ORF2 structural capsid protein 
that coats viral particles.140- 142 Initial primate studies have shown 
antibodies raised against ORF2 complete or truncated proteins pro-
tected against infections.143 HEV vaccines in various stages of de-
velopment have been reviewed Cao et al, 2018.140 Most of these 
vaccines are in preclinical stages and use ORF2 truncated protein 
as an immunogen. Different expression systems are used for the 
development of these vaccines.144,145 It is reported that large- scale 
vaccination campaigns are not as cost- effective as the infections are 
mostly benign in the developing world and were under reported.146 
Because of the economic viability, few vaccines were dropped from 
further development. For example, the HEV GSK candidate vaccine 
was dropped, inspite of a good efficacy in phase II clinical trial.147 
Few vaccines are under development in providing combined efficacy 
against two distinct pathogens; hepatitis A and E, HEV- HBsAg and 
trivalent HEV- RV- AstV vaccines.148
7  | CONCLUSION AND PERSPEC TIVES
Hepatitis E virus infection is much more common than previously 
thought. We are just in the beginning to understand all aspects of 
HEV virology, immunology, the animal reservoir, modes of transmis-
sion and clinical relevance. Moreover, therapeutic strategies and 
vaccine development need further research.
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